// App-Quantinova.ai

S187 : IBERDOMIDE (IBER) IN COMBINATION WITH DEXAMETHASONE (DEX) AND DARATUMUMAB (DARA), BORTEZOMIB (BORT), OR CARFILZOMIB (CFZ) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)

Researchers

Presenter

  • Sagar Lonial

Principal Investigators

  • Paul G. Richardson

  • Rakesh Popat

  • Edward Stadtmauer

  • Jeremy Larsen

  • Albert Oriol

  • Stefan Knop

  • Sundar Jagannath

  • Gordon Cook

  • Ashraf Z. Badros

  • Paula Rodrguez Otero

  • David S. Siegel

  • Tuong Vi Nguyen

  • Antonia Di Micco

  • Alpesh Amin

  • Min Chen

  • Elisabeth Kueenburg

  • Niels W.C.J. van de Donk

Medical Centers

  • Medizinische Klinik und Poliklinik II, Universitatsklinikum Wurzburg, Wurzburg, Germany

  • Winship Cancer Institute of Emory University,Atlanta, GA,Vereinigte Staaten

  • Institut d’Investigació Contra la Leucèmia Josep Carreras and Institut Català d’Oncologia, Hospital Germans Trias i Pujol, Badalona, Spain

  • Penn FTD Center, University of Pennsylvania Philadelphia PA United States

  • The University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland Medical Center, Baltimore, MD

  • NY-Mt Sinai Hospital, New Yrk, New York, United States

  • Clinica Universidad de Navarra-CIMA, IDISNA, CIBERONC, Pamplona, Spain

  • Amsterdam University Medical Center, VU Amsterdam, Department of Hematology, Cancer Center Amsterdam,Amsterdam,Netherlands

  • Division of Multiple Myeloma, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ

  • NIHR Clinical Research Facility, University College London Hospitals, London, United Kingdom

  • Dana-Farber Cancer Institute, Boston, MA, United States

  • Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, United Kingdom

  • Bristol Meyers Squibb,Princeton,United States

  • Mayo Clinic, Scottsdale, Arizona, United States

  • Celgene International Sàrl, a Bristol Myers Squibb Company, Boudry, Switzerland

Locations

  • Germany

  • United States

  • Spain

  • Netherlands

  • United Kingdom

  • Switzerland

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Multiple Myeloma

Biomarkers

  • N/A

Drug/Treatment

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Pomalidomide

  • CC-4047

  • Lenalidomide

  • carfilzomib Intravenous

  • daratumumab Intravenous

  • Bortezomib

  • Sparsentan

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • NA

Study Id's

  • NCT02773030

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved